/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Ademi LLP is investigating EQRx (Nasdaq: EQRX) for possible breaches of fiduciary duty and other violations of law in its transaction with...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Shareholder rights law firm Robbins LLP is investigating EQRx, Inc. (NASDAQ: EQRX) to determine whether certain EQRx officers and directors violated securities laws and breached fiduciary duties to shareholders....
December S&P 500 futures (ESZ22) are trending down -0.40% this morning after three major US benchmark indices closed higher on Friday, demonstrating their strongest weekly advance in almost five months...
The company suspended trials for one of its lead therapies.
Initiated a U.S.-led, comparative Phase 3b clinical trial with aumolertinib for the first-line treatment of EGFR-mutated NSCLCAnnounced U.K. MHRA...
In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstrated a...
Marketing authorization application is EQRx’s first submission to a regulatory agencyApplication is based on data from pivotal Phase 3 AENEAS trial in the...
In a Phase 3 clinical trial, the addition of sugemalimab to chemotherapy improved median overall survival by 8.5 months versus placebo plus chemotherapy in...